Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Landre, G. Justeau, J. Assié, K. Chouahnia, C. Davoine, C. Taleb, C. Chouaïd, B. Duchemann (2021)Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials
Cancer Immunology, Immunotherapy, 71
Study to compare AMG 510 “ Proposed INN Sotorasib ” with docetaxel in non small cell lung cancer ( NSCLC ) ( Code - Break 200 )
L. Gianoncelli, G. Spitaleri, A. Passaro, D. Radice, C. Fumagalli, E. Signore, V. Stati, C. Catania, E. Guerini-Rocco, M. Barberis, F. Marinis (2020)Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis
AntiCancer Research, 40
J. Mazières, A. Drilon, A. Lusque, L. Mhanna, A. Cortot, L. Mezquita, A. Thai, C. Mascaux, S. Couraud, R. Veillon, M. Heuvel, J. Neal, N. Peled, M. Früh, T. Ng, V. Gounant, S. Popat, J. Diebold, J. Sabari, V. Zhu, S. Rothschild, P. Bironzo, A. Martínez-Martí, A. Curioni-Fontecedro, R. Rosell, Mickaël Lattuca-Truc, M. Wiesweg, B. Besse, B. Solomon, F. Barlesi, R. Schouten, H. Wakelee, D. Camidge, G. Zalcman, S. Novello, S. Ou, J. Milia, O. Gautschi (2019)Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Annals of Oncology, 30
F. Skoulidis, Bob Li, G. Dy, T. Price, G. Falchook, J. Wolf, A. Italiano, M. Schuler, H. Borghaei, F. Barlesi, T. Kato, A. Curioni-Fontecedro, A. Sacher, A. Spira, S. Ramalingam, Toshiaki Takahashi, B. Besse, A. Anderson, A. Ang, Q. Tran, O. Mather, H. Henary, G. Ngarmchamnanrith, G. Friberg, V. Velcheti, R. Govindan (2021)Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
The New England journal of medicine
M. Xie, Xiaoling Xu, Yun Fan (2021)KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
Frontiers in Oncology, 11
B. Lan, Chengxi Ma, Chengyan Zhang, S. Chai, Pingli Wang, Liren Ding, Kai Wang (2017)Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis
M. Nagasaka, Yiwei Li, A. Sukari, S. Ou, M. Al-Hallak, A. Azmi (2020)KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Cancer treatment reviews, 84
G. Guaitoli, M. Tiseo, M. Maio, L. Friboulet, F. Facchinetti (2021)Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
Translational Lung Cancer Research, 10
(2019)in patients with KRAS p . G 12 C mutated or wild - type disease
SP Finn, A Addeo, U Dafni, E Thunnissen, L Bubendorf, LB Madsen (2021)Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the European Thoracic Oncology Platform Lungscape Project
J Thorac Oncol, 16
A. Noordhof, R. Damhuis, L. Hendriks, A. Langen, W. Timens, B. Venmans, W. Geffen (2021)Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.
Lung cancer, 155
A. Biernacka, Peter Tsongalis, Jason Peterson, F. Abreu, C. Black, E. Gutmann, Xiaoying Liu, L. Tafe, C. Amos, G. Tsongalis (2016)The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma.
Cancer genetics, 209 5
S. Finn, A. Addeo, U. Dafni, E. Thunnissen, L. Bubendorf, L. Madsen, W. Biernat, E. Verbeken, J. Hernández-Losa, A. Marchetti, R. Cheney, A. Warth, E. Speel, A. Quinn, K. Monkhorst, E. Jantus-Lewintre, V. Tischler, N. Marti, G. Dimopoulou, M. Molina-Vila, R. Kammler, K. Kerr, S. Peters, R. Stahel (2021)Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the ETOP Lungscape Project.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Á. Ghimessy, P. Radeczky, V. Laszlo, B. Hegedűs, F. Rényi-Vámos, J. Fillinger, W. Klepetko, C. Lang, B. Dome, Z. Megyesfalvi (2020)Current therapy of KRAS-mutant lung cancer
Cancer Metastasis Reviews, 39
J. Torralvo, A. Friedlaender, V. Achard, A. Addeo (2019)The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience
Cancer Genomics & Proteomics, 16
C. Lee, J. Man, S. Lord, M. Links, V. Gebski, T. Mok, J. Yang (2017)Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis
Journal of Thoracic Oncology, 12
J. Hunter, A. Manandhar, M. Carrasco, D. Gurbani, S. Gondi, K. Westover (2015)Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Molecular Cancer Research, 13
Terry Ng, Yiwei Liu, A. Dimou, T. Patil, D. Aisner, Z. Dong, T. Jiang, C. Su, Chunyan Wu, S. Ren, Caicun Zhou, D. Camidge (2018)Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer
Hai-xia Yang, S. Liang, R. Schmid, R. Peng (2019)New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Frontiers in Oncology, 9
Meichen Gu, Tiankai Xu, Pengyu Chang (2021)KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
Therapeutic Advances in Medical Oncology, 13
Chengming Liu, Sufei Zheng, Runsen Jin, Xinfeng Wang, Feng Wang, R. Zang, Haiyan Xu, Zhiliang Lu, Jianbing Huang, Yuanyuan Lei, Shuangshuang Mao, Yalong Wang, Xiaoli Feng, N. Sun, Yan Wang, Jie He (2020)The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
J. Kim, H. Kim, B. Kim (2017)Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
A. Davis, W. Cooper, M. Boyer, Jenny Lee, N. Pavlakis, S. Kao (2021)Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations.
R. Team (2014)R: A language and environment for statistical computing.
MSOR connections, 1
H Yang (2019)953
Front Oncol, 9
M. Reck, D. Carbone, M. Garassino, F. Barlesi (2021)Targeting KRAS in non-small cell lung cancer: recent progress and new approaches.
Annals of oncology : official journal of the European Society for Medical Oncology
A. Spira, H. Tu, S. Aggarwal, H. Hsu, G. Carrigan, Xuena Wang, G. Ngarmchamnanrith, V. Chia, J. Gray (2021)A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
Lung cancer, 159
(2020)KRAS(G12C) inhibition with sotorasib in advanced solid tumors
BackgroundKRAS is the most frequently mutated gene in non-small cell lung cancer (NSCLC), however conflicting data are available on its role as a biomarker.ObjectiveThe aim of our work was to investigate the impact of KRAS mutations on response and survival outcomes in advanced non-squamous NSCLC patients treated with immune checkpoint inhibitors alone or in combination with chemotherapy.Patients and MethodsWe retrospectively identified 119 patients, most of whom (58%) were KRAS wild type. For each patient we evaluated overall survival (OS), progression-free survival (PFS), and disease control rate (DCR). An exploratory analysis was performed among KRAS mutated patients to investigate the impact of specific KRAS mutations on response and survival outcomes.ResultsAfter a median follow-up of 10.3 months, the median OS was 14.9 months (95% confidence interval [CI] 7.6–22.7) in wild-type KRAS patients versus 14.7 months (95% CI 8.0–19.5) in mutated KRAS patients (p = 0.529). No differences were detected between the two groups in terms of PFS and DCR. Patients with a KRAS G12C mutation reported survival and response outcomes that were not statistically different from those of patients with other KRAS mutations.ConclusionOur data confirmed that KRAS mutational status is not associated with survival and response outcomes in advanced non-squamous NSCLC patients treated with immunotherapy alone or combined with chemotherapy.
Targeted Oncology – Springer Journals
Published: Jan 1, 2023
Access the full text.
Sign up today, get DeepDyve free for 14 days.